OYRON WELL D-ONE Rev /10/2015

Similar documents
Guidelines for Laboratory Verification of Performance of the FilmArray BCID System

Cipro for gram positive cocci in urine

CUMULATIVE ANTIBIOGRAM

A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya

2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)

A Study on Urinary Tract Infection Pathogen Profile and Their In Vitro Susceptibility to Antimicrobial Agents

Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms

Antimicrobial resistance at different levels of health-care services in Nepal

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Cipro for klebsiella uti

Bacteriological Study of Catheter Associated Urinary Tract Infection in a Tertiary Care Hospital

Quad Plate User s Manual

TEST REPORT. Client: M/s Ion Silver AB. Loddekopinge. Sverige / SWEDEN. Chandran. min and 30 min. 2. E. coli. 1. S. aureus

CONTAGIOUS COMMENTS Department of Epidemiology

Infection Linelist. Infections Occurred Between 10/1/ :00:00 AM To 11/1/ :00:00 AM 2RCW2. Gastroenteritis (Adult) Urinary Tract

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

Antimicrobial Susceptibility Patterns

HardyCHROM MRSA, Contact Plate

FLEXICULT vet UrInary TEsT. SSI Diagnostica

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Intrinsic, implied and default resistance

Concise Antibiogram Toolkit Background

Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India

CONTAGIOUS COMMENTS Department of Epidemiology

Antibiotic Susceptibility of Common Bacterial Pathogens in Canine Urinary Tract Infections

Dr. C. MANIKANDAN, Director,

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Key words: Urinary tract infection, Antibiotic resistance, E.coli.

CultiControl. Technical Sheet 01

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

Int.J.Curr.Microbiol.App.Sci (2017) 6(11):

Understanding the Hospital Antibiogram

SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data

Role of the nurse in diagnosing infection: The right sample, every time

National Surveillance of Antimicrobial Resistance

Isolation of Urinary Tract Pathogens and Study of their Drug Susceptibility Patterns

17June2017. Parampal Deol, Ph.D, MBA Senior Director, R&D Microbiology North America

Gram-positive cocci Staphylococci and Streptococcia

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

Antimicrobial Stewardship Strategy: Antibiograms

Group b strep and macrodantin

Urinary Tract Infections in Hospitalized Newborns in Beheshti Hospital, Iran: A Retrospective Study

Product Name: Uricult Moderately Complex Item Number: Intuition: Title: Title: Discontinued By

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

The Disinfecting Effect of Electrolyzed Water Produced by GEN-X-3. Laboratory of Diagnostic Medicine, College of Medicine, Soonchunhyang University

Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals

2016 Antibiotic Susceptibility Report

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

microbiology testing services

Antimicrobial Susceptibility Testing: Advanced Course

RCH antibiotic susceptibility data

Received 5 February 2004/Returned for modification 16 March 2004/Accepted 7 April 2004

GeNei TM. Antibiotic Sensitivity. Teaching Kit Manual KT Revision No.: Bangalore Genei, 2007 Bangalore Genei, 2007

a. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.

2015 Antibiotic Susceptibility Report

3 Infection Prevention Solutions

CONTAGIOUS COMMENTS Department of Epidemiology

Cost high. acceptable. worst. best. acceptable. Cost low

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

Antibiotic Susceptibility Patterns of Community-Acquired Urinary Tract Infection Isolates from Female Patients on the US (Texas)- Mexico Border

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

6. STORAGE INSTRUCTIONS

Dairy/Milk Testing Report Detecting Elevated Levels of Bacteria in Milk-On-Site Direct- From-The-Cow Within Minutes as Indicator of Mastitis

Antimicrobial Susceptibility Testing: The Basics

European Committee on Antimicrobial Susceptibility Testing

ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao

THE SENSITIVITY OF PATHOGENS OF COMMUNITY-ACQUIRED URINARY TRACT INFECTIONS IN KARAGANDA Ye. A. Zakharova 1, Chesca Antonella 2, I. S.

Tel: Fax:

B. PACKAGE LEAFLET 1

MARBOCYL FD SUMMARY OF PRODUCT CHARACTERISTICS

Overview of Infection Control and Prevention

Regional community-acquired urinary tract infections in Israel: diagnosis, pathogens, and antibiotic guidelines adherence: A prospective study

EcoHydra Antimicrobial Handwash. Product Overview. Physical Properties. Product Description. Regulatory Compliance. Key Features and Benefits

EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING

Test Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

Mastitis and On-Farm Milk Cultures - A Field Study - Part 1

Quality assurance of antimicrobial susceptibility testing

Media Issued by: LABORATORY MANAGER Original Date: April 11, 2001 Approved by: Laboratory Director Revision Date: February 27, 2004

EUCAST recommended strains for internal quality control

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria

Biofilm eradication studies on uropathogenic E. coli using ciprofloxacin and nitrofurantoin

Antimicrobial Stewardship in Continuing Care. Urinary Tract Infections Clinical Checklist

Can levaquin treat group b strep

Original Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):

Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Urinary Tract Infection: Study of Microbiological Profile and its Antibiotic Susceptibility Pattern

BIOLACTAM. Product Description. An innovative in vitro diagnostic for the rapid quantitative determination of ß-lactamase activity

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

UTI Dr S Mathijs Department of Pharmacology

General Approach to Infectious Diseases

European Committee on Antimicrobial Susceptibility Testing

MICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC

Transcription:

OYRON Well D-ONE System for the presumptive identification and antimicrobial susceptibility test of most common microorganisms in urinary tract infections 1. INTRODUCTION Urinary tract infections (UTI) are one of the most frequent infectious diseases both in the community and in hospitals. Not only represent a clinical problem, but also have an economic impact on healthcare costs that represent. Microbiological diagnosis has been modified in recent years, and actually it is recommended to consider the recount of colony-forming units together with clinical aspects (cystitis, asymptomatic bacteriuria), patient gender presence of urethral catheter etc.. For pregnant women the detection of Streptococcus agalactiae is very important for a specific treatment, in order to prevent neonatal sepsis that may be caused by this agent; over 95 % of UTIs are caused by a single bacterial species, Escherichia coli which causes about 75-95 % of episodes of acute uncomplicated cystitis. Staphylococcus aureus, Proteus mirabilis, Klebsiella pneumoniae, Streptococcus agalactiae, Enterobacter spp. and Enterococcus spp. are responsible for the vast majority of the other urinary tract infections (1) (2) (3). This system is designed to detect microorganisms in urine samples obtained in different ways. The concentration (CFU / ml) is sometimes difficult to perform due to various factors, sometimes unnecessary in cases specific such as pregnant women, elderly, disabled patients under special treatment, clinical follow up previous infections, another cases. Based on the results obtained with the kit Oyron Well D-ONE, complementary tests, signs and symptoms, and the criteria of the clinician, the results of this kit and the decision of antimicrobial treatment and complementary tests will are taken into account. 2. PRINCIPLE System composed of a polypropylene plate containing 32 conical wells for better viewing of the colorimetric reactions that occur as result of the growth of microorganisms in specially formulated media for selective culture of: Escherichia coli, Streptococcus agalactiae, Staphylococcus aureus, Enterobacter spp., Enterococcus spp., Proteus/Providencia group, Pseudomonas spp., KES group (Klebsiella, Enterobacter, Serratia), Candida spp., Candida albicans. Microbiological diagnosis can be confirmed by serological tests, microscopic examination or culture of positive wells directly. 3. OYRON WELL D-ONE KIT CONTENTS (REF. MS01285) 10 Identification panel (REF. MS01285) 10 x 10 ml Saline Solution (REF. MS01304) Reagent A (Naphthylamine) 1 x 1 ml (REF. MS01304) Reagent B (Sulfanilic Acid) 1 x 1 xml (REF. MS01311) (Bring the Reagent B to room temperature, before use) 4. REAGENTS REQUIRED BUT NOT PROVIDED Laboratory equipment.

5. COMPOSITION OF TEST PLATE Well 1: Culture Medium for detection of N0 2 Well 2: Culture Medium for Growth Control Well 3: Culture Medium for Gram Negative bacteria presumptive detection Well 4: Selective Medium for Gram Positive bacteria presumptive detection Well 5:Selective Medium for the presumptive identification of Escherichia coli Well 6: Selective Medium for the presumptive identification of Escherichia coli Well 7: Selective Medium for presumptive identification of Streptococcus agalactiae Well 8: Selective Medium for presumptive identification of Streptococcus agalactiae Well 9: Selective Medium for presumptive identification of Pseudomonas spp. Well 10: Selective Medium for presumptive identification of Staphylococcus aureus Well 11: Selective Medium for presumptive identification of Staphylococcus aureus Well 12: Selective Medium for presumptive identification of Enterobacter spp. Well 13: Selective Medium for presumptive identification of Enterobacter spp. Well 14: Selective Medium for presumptive identification of Proteus/Providencia Well 15: Selective Medium for presumptive identification of Proteus/Providencia Well 16: Selective Medium for presumptive identification of KES group (Klebsiella, Enterobacter, Serratia) Well 17: Selective Medium for presumptive identification of Enterococcus spp. Well 18: Selective Medium for presumptive identification Candida albicans Well 19: Selective Medium for presumptive identification Candida spp. Well 20: Culture medium containing Fosfomycin 256 µg/ml Well 21: Culture medium containing Amikacin 32 µg/ml Well 22: Culture medium containing Gentamicin 8 µg/ml Well 23: Culture medium containing Piperacillin/Tazobactam 128/4 µg/ml Well 24: Culture medium containing Cefoperazone 64 µg/ml Well 25: Culture medium containing Cefotaxime 64 µg/ml Well 26: Culture medium containing Ceftazidime 32 µg/ml Well 27: Culture medium containing Ampicillin/Sulbactam 32/16 µg/ml Well 28: Culture medium containing Nalidixic Acid 32 µg/ml Well 29: Culture medium containing Ciprofloxacin 4 µg/ml Well 30: Culture medium containing Levofloxacin 8 µg/ml Well 31: Culture medium containing Amoxicillin/Clavulanic Acid 32/16 µg/ml Well 32: Culture medium containing Cotrimoxazol 8 µg/ml

6. ASSAY METHOD 6.1 SAMPLE COLLECTION AND PREPARATION Samples: Urine, suprapubic aspirations, urinary catheterization. The sample must be obtained according to the procedure established in each hospital. The urine sample must correspond with the first morning urine. For children under 5 years follow the recommended procedure to avoid contamination of specimens. Urine samples obtained by catheterization or suprapubic aspiration are obtained according to medical prescriptions and trained personnel. Specimens should be obtained before starting antimicrobial treatment or after at least three days to complete the same treatment. For the best performance of this system the sample must be taken aseptically according to the methodology implemented in each hospital center. The sample should be processed immediately after collection; if that is not possible, specimens may be refrigerated at 2 to 8 C for up to 24 hours and not more. Protect from light and sun. The results obtained with OYRON Well D-ONE method should be compared to the traditional methods of analysis of the urine sample established in each laboratory. 6.2 TEST PROCEDURE Take 200 µl (4 drops) of the sample and dilute in the saline solution vial provided in the kit. Homogenize the solution with a Pasteur pipette or automatic pipette. Aliquot 150 µl (3 drops) of the suspension obtained in each of the 32 wells of the kit. Incubate at 37 C for 24 hours (for Candida spp. 48 hours) In the case of well 1 add 1 drop of Reagent A and 1 drop of Reagent B and wait for 5 minutes the color change. In the case of well 19 a microscopic observation (40X) of the growth of chlamydospores and / or hyphae is recommended. 7. INTERPRETATION OF RESULTS The results are evidenced by color changes that occur in wells according to reactions due to chemical or chromogenic components contained in specific formulations for each microorganism. The results obtained with OYRON WELL D-ONE should be analyzed together with the results obtained with traditional methods of microscopic staining and / or cell counting and other analysis of the sample, and examinations established in each laboratory. The results must be qualified and evaluated according to the recommendations of this IFU. For the interpretation of results, read carefully the Instruction manual and interpretation of results and the Reaction Table attached. 8. WARNING AND PRECAUTIONS 1. For professional and in vitro diagnostic use only, not to be used by the general public. 2. The samples have to be treated as potentially infectious and the test must be carried out only by trained personnel. 3. Do not open the sealed pouch unless ready to perform the assay. 4. Do not use expired devices.

5. Do not use components from any other type of test kit as a substitute for the components in this kit. 6. Wear protective clothing and disposable gloves while handling the kit reagents and clinical specimens. Wash hands thoroughly after performing the test. 7. Do not smoke, drink or eat in areas where specimens or kit reagents are being handled. 8. Dispose of all specimens and materials used to perform the test as bio-hazardous waste. 9. LIMITATIONS Samples collected after antimicrobial treatment. Samples collected inadequately. Urine samples containing two or more microorganisms may cause different color change in identification wells and in antimicrobial susceptibility wells. Read with attention this Instruction for use prior to realize the test in order to avoid errors. The test have to be interpreted by microbiologist specialist. 10. QUALITY CONTROL Each batch of OYRON Well D-ONE is submitted to a rigorous quality control with the following bacterial reference strains: Escherichia coli ATCC 25922 Staphylococcus aureus ATCC 25923 Proteus mirabilis ATCC 25933 Enterococcus faecalis ATCC 19433 Candida albicans ATCC 10231 Candida krusei ATCC 6258 Candida glabrata ATCC 90030 Candida tropicalis ATCC 750 Enterococcus faecalis ATCC 29212 Enterobacter spp ATCC 13047 ATCC 13048 Staphylococcus saprophyticus ATCC 15305 Pseudomonas aeruginosa ATCC 27853 Candida albicans ATCC 10231 Klebsiella pneumoniae ATCC 13883 Streptococcus agalatiae ATCC 13813 11. STORAGE Store at 2-8 C in its original package. Do not store near heat sources and avoid extreme temperature variations. Under these conditions the product is valid until the expiration date indicated on label. Do not use after this date. Discard if there are signs of deterioration. 12. BIBLIOGRAPHY 1. Edwards MS, Nizet V, Baker CJ. Group B Streptococcal Infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011:419. 2. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010 Mar 1;50(5):625-63. 3.- Validazione del Sistema OYRON Well D-ONE in campioni da Infezioni delle vie Urinarie. Comparazione con metodi tradizionali. OYRON Well D-ONE Technical File, C.P.M. sas, 2013. 4. NCCLS. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 2000. Fifth

Edition. Approved Standard M7-A5. Wayne, PA, USA. 5.NCCLS. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 2002; 22(1). Approved Standard M2-A5, Wayne, PA, USA. Index of symbols Reference code LOT number Expiration date Temperature limitation/store between For in vitro diagnostic use Do not reuse Fragile, handle with care Consult Instructions for Use Manufacturer Contains sufficient for <n> tests Conform to the Directive 98/79/EC on in vitro diagnostic medical device C.P.M. sas Via degli Olmetti, 5 00060 (Zona Ind.le) Formello, (ROMA), Italia Tel. +39/06.90.400.126 +39/06.90.75.531 - Fax. +39/06.90.405.270 www.cpmsas.it - cpm@cpmsas.it

WELL REACTIONS TABLE POSITIVE COLORIMETRIC REACTION NEGATIVE Well 1: Culture Medium for detection of N0 2 /Dark orange Yellow Well 2: Culture Medium for Growth Control Well 3: Culture Medium for Gram Negative bacteria presumptive detection Well 4: Selective Medium for Gram Positive bacteria presumptive detection Well 5: Selective Medium for the presumptive identification of Escherichia coli Well 6: Selective Medium for the presumptive identification of Escherichia coli Well 7: Selective Medium for presumptive identification of Streptococcus agalactiae Well 8: Selective Medium for presumptive identification of Streptococcus agalactiae Well 9: Selective Medium for presumptive identification of Pseudomonas spp. Well 10: Selective Medium for presumptive identification of Staphylococcus aureus Well 11: Selective Medium for presumptive identification of Staphylococcus aureus Well 12: Selective Medium for presumptive identification of Enterobacter spp. Well 13: Selective Medium for presumptive identification of Enterobacter spp. Well 14: Selective Medium for presumptive identification of Proteus/Providencia Well 15: Selective Medium for presumptive identification of Proteus/Providencia Well 16: Selective Medium for presumptive identification of KES group (Klebsiella *, Enterobacter**, Serratia***) Well 17: Selective Medium for presumptive identification of Enterococcus spp. Well 18: Selective Medium for presumptive identification Candida albicans. Well 19: Selective Medium for presumptive identification Candida spp. Strong Yellow Turbid Aqua Green Blue Green Turbid Yellow Turbid Aquamarine Green Violet/Dark purple Black with precipitate Turbid white Turbid Pink Dark Brown/Black Dark Brown/Black *green/**dark blue/ ***variable Black Green Turbid Yellow Turbid Yellow White/Very slight yellow White/very slight /Other colors Transparent yellow White/other colors/transparent /other colors /slight gray Slight yellow/transparent /transparent/other colors Yellow Yellow Blue

Well 20: Culture medium containing Fosfomycin 256 µg/ml ANTIBIOTIC SUSCEPTIBILITY TEST RESISTENT SUSCEPTIBLE Well 21: Culture medium containing Amikacin 32 µg/ml Well 22: Culture medium containing Gentamicin 8 µg/ml Well 23: Culture medium containing Piperacillin/Tazobactam 128/4 µg/ml Well 24: Culture medium containing Cefoperazone 64 µg/ml Well 25: Culture medium containing Cefotaxime 64 µg/ml Well 26: Culture medium containing Ceftazidime 32 µg/ml Well 27: Culture medium containing Ampicillin/Sulbactam 32/16 µg/ml Well 28: Culture medium containing Nalidixic Acid 32 µg/ml Well 29: Culture medium containing Ciprofloxacin 4 µg/ml Well 30: Culture medium containing Levofloxacin 8 µg/ml Well 31: Culture medium containing Amoxicillin/Clavulanic Acid 32/16 µg/ml Well 32: Culture medium containing Cotrimoxazol 8 µg/ml Turbid Turbid C.P.M. sas Via degli Olmetti, 5 00060 (Zona Ind.le) Formello, (ROMA), Italia Tel. +39/06.90.400.126 +39/06.90.75.531 - Fax. +39/06.90.405.270 www.cpmsas.it - cpm@cpmsas.it